1.53  0.07 (4.79%)		11-04 16:00
Open: 1.58 High: 1.59 Volume: 72,072		Pre. Close: 1.46 Low: 1.53 Market Cap: 7(M)

Short term
Mid term
Targets	6-month :	2	1-year :	2.34
Resists	First :	1.72	Second :	2
Pivot price	1.25
Supports	First :	1.33	Second :	1.1
MAs	MA(5) :	1.33	MA(20) :	1.27
	MA(100) :	1.42	MA(250) :	1.6
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	72.5	D(3) :	55.1
RSI	RSI(14): 62.2
52-week	High :	2.57	Low :	0.83

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ALZN ] has closed Bollinger Bands are 32.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.59 - 1.6	1.6 - 1.6
Low:	1.51 - 1.52	1.52 - 1.53
Close:	1.52 - 1.53	1.53 - 1.54

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Tue, 03 Nov 2026
Alzamend Neuro, Inc. (ALZN) Seasonal returns chart - Yahoo Finance - Yahoo Finance Singapore

Mon, 02 Nov 2026
Alzamend Neuro, Inc. (ALZN) Seasonal returns chart - Yahoo Finance UK

Sun, 25 Oct 2026
Alzamend Neuro, Inc. Estimates – BOATS:ALZN - TradingView

Fri, 09 Oct 2026
No shares sold: Alzamend Neuro (ALZN) requests withdrawal of a resale registration. - Stock Titan

Thu, 08 Oct 2026
Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Wed, 16 Sep 2026
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	5 (M)
Shares Float	5 (M)
Held by Insiders	2.6 (%)
Held by Institutions	52 (%)
Shares Short	112 (K)
Shares Short P.Month	158 (K)

EPS	-2.3
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.2
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-76.5 %
Return on Equity (ttm)	-163.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.86
Qtrly Earnings Growth	0 %
Operating Cash Flow	-7 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-0.67
PEG Ratio	0
Price to Book value	1.27
Price to Sales	0
Price to Cash Flow	-1.09

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.